Literature DB >> 3335033

Mechanisms of induction of ornithine decarboxylase activity in tracheal epithelial cells by asbestiform minerals.

J P Marsh1, B T Mossman.   

Abstract

Asbestos induces a constellation of biological responses in cells of the respiratory tract that are similar to those of classical tumor promoters. In this regard, induction of ornithine decarboxylase (ODC) activity and increased incorporation of [3H]thymidine have been documented after addition of crocidolite and chrysotile asbestos to a hamster tracheal epithelial cell line (J. M. Landesman and B. T. Mossman, Cancer Res., 42:3669-3675, 1982). The objectives of studies here were to determine: (a) the importance of geometry, size, and/or chemical composition of asbestos fibers on induction of ODC activity; and (b) the possible involvement of calcium and/or protein kinase C in asbestos-induced ODC activity. After addition for 24 h to confluent hamster tracheal epithelial cells, fibers of crocidolite, chrysotile, and glass in medium containing fresh serum caused a significant increase in ODC activity. Stimulation of ODC was not observed when nonfibrous analogues (riebeckite, antigorite, and glass particles) were used. Sized preparations of long (greater than 10-micron length) chrysotile fibers were more potent in enhancing ODC activity than shorter (less than or equal to 2-micron length) fibers at similar concentrations. The mechanisms of ODC induction by asbestos were probed by adding the calcium channel blockers (verapamil and nifedipine) and inhibitors [10(-5) to 10(-7)M of 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine, of N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide, of TMB-8, and of palmitoyl carnitine] of protein kinase C simultaneously with chrysotile asbestos. These agents inhibited ODC activity by chrysotile in a dosage-dependent fashion. Results suggest that the fibrous geometry and length of asbestos fibers are critical in initiating ODC activity in airway epithelial cells. Moreover, they implicate the importance of calcium and protein kinase C in asbestos-induced mitogenic responses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335033

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Assessment of the pathogenic potential of asbestiform vs. nonasbestiform particulates (cleavage fragments) in in vitro (cell or organ culture) models and bioassays.

Authors:  Brooke T Mossman
Journal:  Regul Toxicol Pharmacol       Date:  2007-10-11       Impact factor: 3.271

2.  Incorporation of tritiated thymidine by epithelial and interstitial cells in bronchiolar-alveolar regions of asbestos-exposed rats.

Authors:  A R Brody; L H Overby
Journal:  Am J Pathol       Date:  1989-01       Impact factor: 4.307

3.  Persistent induction of c-fos and c-jun expression by asbestos.

Authors:  N H Heintz; Y M Janssen; B T Mossman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

4.  Mechanisms of asbestos carcinogenesis and toxicity: the amphibole hypothesis revisited.

Authors:  B T Mossman
Journal:  Br J Ind Med       Date:  1993-08

5.  Hydrolysis of inositol phospholipids precedes cellular proliferation in asbestos-stimulated tracheobronchial epithelial cells.

Authors:  A Sesko; M Cabot; B Mossman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 6.  Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy.

Authors:  L W Jin; T Saitoh
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

7.  Modulation of cellular processes by H7, a non-selective inhibitor of protein kinases.

Authors:  J S Nixon; S E Wilkinson; P D Davis; A D Sedgwick; J Wadsworth; D Westmacott
Journal:  Agents Actions       Date:  1991-03

8.  Dose-Response Relationships in Expression of Biomarkers of Cell Proliferation in in vitro Assays and Inhalation Experiments.

Authors:  Arti Shukla; Pamela Vacek; Brooke T Mossman
Journal:  Nonlinearity Biol Toxicol Med       Date:  2004-04

9.  Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.

Authors:  Sonya Haslam; Paul Chrisp
Journal:  Core Evid       Date:  2007-03-31

10.  Interaction of amosite and surface-modified amosite with a V79-4 (Chinese hamster lung) cell line.

Authors:  E A Sara; R C Brown; C E Evans; J A Hoskins; C F Simpson
Journal:  Environ Health Perspect       Date:  1990-04       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.